Introducing human papillomavirus vaccines—questions remain

References

• zur Hausen H., Gissmann L., Steiner W., Dippold W., Dreger I. Human papillomaviruses and cancer. Bibl Haematol 1975; 43: 569–71
   Google Scholar
• Ho G. Y., Bierman R., Beardsley L., Chang C. J., Burk R. D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 423–8
   PubMed Web of Science ®Google Scholar
• Parkin D. M., Whelan S. L., Ferlay J., Teppo L., Thomas D. B. Cancer incidence in 5 continents. IRAC Scientific Publication 155. International Agency for Reseach of Cancer, LyonFrance 2002; 8
   Google Scholar
• Kalliala I., Anttila A., Pukkala E., Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 2005; 331: 1183–5
   PubMed Web of Science ®Google Scholar
• Edgren G., Saprén P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population‐based study. Lancet Oncol 2007; 8: 311–6
   PubMed Web of Science ®Google Scholar
• D'Souza G., Kreimer A., Viscidi R., Pawlita M., Fakhry C., Koch W. M., et al. Case‐control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944–56
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high‐grade cervical lesions. N Engl J Med 2007; 356: 1915–27
   PubMed Web of Science ®Google Scholar
• Ault K. A., FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus‐like‐particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861–8
   PubMed Web of Science ®Google Scholar
• Paavonen J., Jenkins D., Bosch F. X., Naud P., Salmerón J., Wheeler C. M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus‐like‐particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double‐blind, randomised controlled trial. Lancet 2007; 369: 2161–70
   PubMed Web of Science ®Google Scholar
• Garland S. M., Hernandez‐Avila M., Wheeler C. M., Perez G., Harper D. M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928–43
   PubMed Web of Science ®Google Scholar
• Joura E. A., Leodolter S., Hernandez‐Avila M., Wheeler C. M., Perez G., Koutsky L., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus‐like‐particle vaccine against high‐grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet 2007; 369: 1693–702
   PubMed Web of Science ®Google Scholar
• Harper D. M., Franco El., Wheeler C. M., Moscicki A‐B., Romanowski B., Roteli‐Martins C., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus‐like particle vaccine against human papillomavirus types 16 and 18: follow‐up from a randomised control trial. Lancet 2006; 367: 1247–55
   PubMed Web of Science ®Google Scholar
• Sawaya G. F., Smith‐McCune K. HPV vaccination—more answers, more questions. N Engl J Med 2007; 356: 1991–3
   Web of Science ®Google Scholar
• Kahn J. A., Burk R. D. Papillomavirus vaccines in perspective. Lancet 2007; 369: 2135–7
   PubMed Web of Science ®Google Scholar
• Villa L., for the FUTURE I and II Study Group. Quadrivalent human papillomavirus (HPV) type 6, 11, 16, 18 L1 virus‐like particle vaccine: an analysis of cross‐protection against cervical intraepithelial neoplasia caused by non‐vaccine types., EUROGIN 2007, Monte Carlo, October 4–6, 2007. Abstracts SS2‐2
   Google Scholar
• Lehtinen M., Herrero R., Mayaud P., Barnabas R., Dillner J., Paavonen J., et al. Studies to assess the long‐term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006; 24: S233–41
   Web of Science ®Google Scholar
• Gostin L. O., DeAngelis C. D. Mandatory HPV vaccination: public health vs. private wealth. JAMA 2007; 297: 1921–3
   PubMed Web of Science ®Google Scholar
• Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med 2006; 355: 2389–91
   PubMed Web of Science ®Google Scholar
• Charo R. A. Politics, parents, and prophylaxis—mandating HPV vaccination in the United States. N Engl J Med 2007; 356: 1905–8
   PubMed Web of Science ®Google Scholar